Abstract:BACKGROUND: The RAS/RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathways all belong to mitogen-activated protein kinase (MAPK) signaling pathways, Mutations in any one of the upstream genes (such as the RAS gene or the BRAF gene) may be transmitted to the protein through transcription or translation, resulting in abnormal activation of the signaling pathway. This study investigated the relationship between the KRAS gene mutation and the clinicopathological features and prognosis of colorectal cancer (CRC), and the effect of KRAS mutations on its associated proteins in CRC, with an aim to clarify the cause of tumor progression and drug resistance caused by mutation of the KRAS gene.AIM: To investigate the KRAS gene and RAS pathway signaling molecules in CRC and to analyze their relationship with clinicopathological features and prognosis.METHODS: Colorectal cancer tissue specimens from 196 patients were analyzed for KRAS mutations using quantitative polymerase chain reaction and for KRAS, BRAF, MEK, and ERK protein expression levels using immunohistochemistry of tumor microarrays. To analyze differences of RAS pathway signaling molecule expression levels in different KRAS gene status, the relationships between these parameters and clinicopathological features, 4-year progression-free survival, and overall survival were analyzed by independent sample t test, Kaplan-Meier plots, and the log-rank test. Predictors of overall and disease-free survival were assessed using a Cox proportional hazards model.RESULTS: Of the 196 patients, 62 (32%) carried mutations in codon 12 (53/62) or codon 13 (9/62) in exon 2 of the KRAS gene. KRAS, BRAF, ERK, and MEK protein expression was detected in 71.4%, 78.8%, 64.3%, and 50.8% of CRC tissues, respectively. There were no significant differences between KRAS mutation status and KRAS, BRAF, MEK, or ERK protein levels. Positive expression of KRAS and ERK was associated with poor tumor differentiation, and KRAS expression was also associated with age < 56 years. MEK expression was significantly associated with distant metastasis (P < 0.05). The 4-year progression-free survival rate, but not overall survival rate, was significantly higher in patients with KRAS-negative tumors than in those with KRAS-positive tumors (P < 0.05), whereas BRAF, MEK, and ERK expression was unrelated to survival. Multivariate analysis showed that only the expression of KRAS protein was a risk factor for tumor recurrence (P < 0.05). No other clinicopathological factors correlated with KRAS, BRAF, MEK, or ERK expression.CONCLUSION: KRAS gene mutations do not affect downstream protein expression in CRC. KRAS protein is associated with poor tumor differentiation, older age, and a risk of tumor recurrence.

Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations

KRAS mutation status between left- and right-sided colorectal cancer: are there any differences in computed tomography?

Clinicopathologic Features and Prognostic Value of KRAS, NRAS and BRAF Mutations and DNA Mismatch Repair Status: A Single‐center Retrospective Study of 1,834 Chinese Patients with Stage I–IV Colorectal Cancer

KRAS and BRAF Gene Mutations and DNA Mismatch Repair Status in Chinese Colorectal Carcinoma Patients.

Comprehensive analysis of gene mutations and mismatch repair in Chinese colorectal cancer patients

The Relationship Between Mismatch Repair (MMR) Proteins Status and the Response to Conventional Neoadjuvant Therapy in Colorectal Cancer (CRC).

Analysis of clinical characteristics of mismatch repair status in colorectal cancer: a multicenter retrospective study

KRAS, NRAS, BRAF Signatures, and MMR Status in Colorectal Cancer Patients in North China

Clinic-pathological characteristics of MMR protein, KRAS-NRAS-BRAF gene mutation, HER-2 and PD-L1 status in 3822 Chinese colorectal cancer patients

The Molecular Heterogeneity of Sporadic Colorectal Cancer with Different Tumor Sites in Chinese Patients

KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer.

Mutations of KRAS and BRAF in Chinese Patients with Colorectal Carcinoma : Analyses of 966 Cases

Coexistence of Msi with Kras Mutation is Associated with Worse Prognosis in Colorectal Cancer

The Correlation Between DNA Mismatch Repair Status and the Clinicopathological and Molecular Features of Chinese Sporadic Colorectal Cancer

[Difference analysis of somatic mutations between deficient mismatch repair and proficient mismatch repair gene related with colorectal cancer]

The Relationship Between DNA Mismatch Repair Status and Clinicopathologic Characteristics in Colon Cancer

Prognostic Impact of High-Risk Factors and KRAS Mutation in Patients with Stage II Deficient Mismatch Repair Colon Cancer: a Retrospective Cohort Study

Prevalence and characteristics of PIK3CA mutation in mismatch repair-deficient colorectal cancer.

Serum Tumor Markers Combined With Clinicopathological Characteristics for Predicting MMR and KRAS Status in 2279 Chinese Colorectal Cancer Patients: A Retrospective Analysis

Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer

Microsatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanisms